Download PDF

Register to download the report. Already a member?

Sign Up


59459 1490631916HCLSReviewIrelandMarch2017.pdf
Energy Boardroom

Serbia Pharma Report

August 2011


  • No News

Top Story


Serbia : Serbia: Ready to Flourish

Serbia has had an undoubtedly troubled history since the breakup of Yugoslavia in the early 1990s. A costly war and ensuing UN sanctions have left the country’s economy a few years behind those of its regional counterparts. The subsequent global financial crisis in the late 2000s resulted in another hit to many of the country’s key industries, including Serbia’s pharmaceutical and healthcare sectors. These historical events explain some of the key issues that underlie the sectors’ current challenges, such as non-liquidity and inadequate funding. And while Serbia’s population currently amounts to roughly 7.3 million inhabitants, ‘it is a little-known fact that 1.2 million people have no income, and that the state provides 520 dinars (roughly $7.30) per year for them,’ asserts Serbia’s Ministry of Health.

view more

snapshot in figures

Clinical trials in Serbia

  • Associations view more
  • Interviews


    Interview with Zoran Labudovic, General Manager, Pfizer Serbia

    Pfizer is increasingly interested in emerging markets, with a focus very much on Latin America and Asia. Given this, why is Serbia exciting for Pfizer today? Serbia is interesting for most multinational companies, firstly because of the county’s geographic location, …

    view more

    Download PDF

    First Name:

    Last Name: